Therefore, serum HMGB1 may serve as a potential biomarker for the early diagnosis of NAFLD and as a target for therapies aimed at the prevention and treatment of NAFLD-associated inflammation. Here, HMGB1 is linked to metabolic dysfunction-associated steatotic liver disease.